Revision History

1 revisions for "The Pill That Could Reshape Obesity Treatment: Inside the FDA's Approval of Lilly's Foundayo and the Battle for a $100 Billion Market"

Anonymous1 day ago

The FDA approved Eli Lilly's Foundayo (orforglipron) on April 1, 2026, making it the second oral GLP-1 drug cleared for weight management and intensifying competition with Novo Nordisk's Wegovy pill in a market projected to reach $100 billion by 2027. While the approval expands options for the estimated 100 million obese American adults, questions persist about modest efficacy compared to injectables, long-term safety data spanning fewer than five years, weight regain after discontinuation, and whether insurance and Medicare coverage gaps will leave millions of lower-income patients without access.